.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF01_Palbociclib.Palbociclib

Information

Palbociclib is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is an FDA- and EMA-approved antineoplastic agent administered in combination with endocrine therapy.

Pharmacokinetics

Population pharmacokinetics in adult advanced breast cancer patients, both female and male (predominantly female), mean age ~57 years, oral dosing.

References

1. Royer, B, et al., & Schmitt, A (2021). Population Pharmacokinetics of Palbociclib in aReal-World Situation. Pharmaceuticals (Basel, Switzerland) 14(3) –. DOI:10.3390/ph14030181 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33668400

2. Yu, Y, et al., & Wang, D (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. Cancer chemotherapy and pharmacology 86(6) 701–710. DOI:10.1007/s00280-020-04163-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33037918

3. Panetta, JC, et al., & Stewart, CF (2024). Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors. Pharmaceutics 16(12) –. DOI:10.3390/pharmaceutics16121528 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39771507

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)